for up to 4 weeks enhanced pulsatile GH release, significantly increased serum GH and IGF-I concentrations, and, at a dose of 25 mg/day, restored serum IGF-I concentrations to those of young adults. (J Clin Endocrinol Metab 81: 4249-4257, 1996) P ULSATILE secretion of GH by the anterior pituitary gland is controlled mainly by two hypothalamic peptides: somatostatin, which is inhibitory, and GH-releasing hormone (GHRH), which is stimulatory (1). In addition to stimulating linear growth before epiphyseal fusion, GH has metabolic effects that persist throughout life. These effects are exerted directly by GH and via its stimulation of insulinlike growth factor I (IGF-I) production (1). In physiological concentrations, GH is anabolic, stimulates muscle development and strength, stimulates loss of fat tissue (particularly from central abdominal sites), and increases bone density (2). GH also exerts cardioprotective effects on blood lipid concentrations, explaining why adult GH deficiency may predispose to premature atherosclerosis and the resultant increased mortality from cardiovascular disease (2, 3).
Normal human aging is associated with declining serum concentrations of GH and IGF-I (4-7). Although normal aging is not typically associated with profound GH deficiency as occurs in patients with pituitary disease (8, 9), mean GH concentrations in people over 60 yr of age are, on the average, about one third to one half those in young adults (4, 9-11). This reduction may contribute to the decreases in muscle and bone mass and the increases in adipose tissue that accompany normal aging (12). These changes have been partially reversed by GH administration for 6 months to otherwise healthy older men and women (13, 14) . The disadvantages of GH therapy are the high cost, the need for parenteral administration, and side-effects, including fluid retention, carpal tunnel syndrome, and glucose intolerance (2, (12) (13) (14) . We speculate that such side-effects may result from prolonged nonphysiological elevations of circulating GH concentrations after daily SC GH injections (15). If this is the case, enhancement of endogenous pulsatile GH secretion by an 4249 Downloaded from https://academic.oup.com/jcem/article-abstract/81/12/4249/2650464/Stimulation-of-the-growth-hormone-GH-insulin-like by guest on 28 September 2017 orally administered secretagogue may be a more desirable therapeutic strategy than parenteral GH.
GH-releasing peptide (GHRP) is a synthetic hexapeptide that was developed specifically to stimulate growth. It stimulates pulsatile GH secretion in humans, probably by actions on both the hypothalamus and pituitary, through a novel receptor (16) (17) (18) . The natural ligand, whose effect it mimics, has yet to be discovered. Compounds have been developed that mimic the stimulatory actions of GHRP on GH release and do not interact with muscarinic or nicotinic cholinergic receptors (19, 20) . These compounds are more potent secretagogues than GHRH in older adults (21). We report the effects of oral administration for 2-4 weeks of the spiropiperidine to healthy older adults. This compound was selected because of its high oral bioavailability and its long duration of action.
Expeti.mental Subjects 
Materials and Methods
Study design (Fig. 1) Subjects were entered into a randomized, double blind, placebocontrolled trial, in which they received once daily the oral study drug or placebo) for each of two 14-day study periods (periods I and II) separated by a 14-to 21-day washout period. At the end of period II, subjects received the study drug for an additional 2-week extension period for collection of IGF-I and safety data. Subjects were studied in one of two panels. In panel A, the study drug was given once a day in the evening (between 2200-2300 h). In panel B, subjects received the study drug in both the morning (between 0700-0900 h) and the evening (between 2200-2300 h); to blind the treatment time of the active drug, at least one of these two treatments per day was placebo.
Period 1. Subjects were admitted to the Clinical Research Center (CRC) the day before the study, to acclimate to the unit. Regular CRC diets were consumed during all admissions. Alcohol consumption was not permitted. An iv cannula for blood sampling was inserted into an arm vein by 0700 h on study day 1. Starting at 0800 h on study day 1, blood samples were collected every 20 min for 24 h for measurement of GH, cortisol, and PRL, and a 24-h urine collection was started for measurement of urinary free cortisol. At 0900 h on the next day (study day 2), 1 h after completion of sampling, subjects received the first dose of the study drug; from study days 3-15, subjects took the study drug between 2200 -2300 h (and also between 0700 -0900 h in panel B). Compliance was monitored by drug log and Smart-Cap (APREX Corp., Fremont, CA), a top for the medication container that contains a sensor and monitoring device to record each time the container is opened. Subjects were instructed to consume no more than six cups of caffeinated beverages and two alcoholic drinks per day during this period, but had no other dietary limitations.
They were instructed to avoid strenuous exercise, but encouraged to continue modest exercise as part of their daily routine. Subjects were readmitted to the CRC in the evening of study day 14 and underwent repeat 24-h blood and urine collections beginning at 0800 h on study day 15, as on study day 2. The last dose of treatment drug was taken in the evening of study day 15.
Period II. After a washout period of 14-21 days, subjects returned to the CRC, took the first dose of the study drug at 0900 h, were observed for 4 h, and then were discharged.
The remainder of the period was the same as period I, with repeat admission and sampling after 2 weeks. Subjects in panels A and B continued to take study drug for an additional 2-week extension period (i.e. a total of 28 continuous days of drug administration) and were then seen for assessment of possible side-effects and collection of fasting urine and blood samples.
Analytical methods
Assays. Serum GH concentrations were measured in duplicate by chemiluminescence assay (Nichols Institute Diagnostics, San Juan Capistrano, CA), modified as previously described (22). The sensitivity of the assay was 0.002 pg/L, and the measured GH concentrations in all samples were above this detection limit. The intraassay coefficients of variation were 5.4% at 0.04 pg/L, 4.8% at 0.4 PgJL, 5.7% at 3.4 wg/L, and 9.9% at 8.4 pg/L.
The interassay coefficients of variation were 5.6% at 0.04 pg/L and 7.9% at 8.4 pg/L. All 24-h GH profiles from each subject were run in one assay. which were statistically significant for treatment with 10 and 25 mg, but not 2 mg MK-677 (Table 1) . After 2 weeks of placebo administration, there was no significant change in mean 24-h GH concentrations (8 ? 16% greater than at baseline; P = NS), whereas the increases were 57 2 13% and 97 of: 23% (range, 30-330%) with 10 and 25 mg MK-677, respectively (P < 0.05 VS. baseline for both doses; Fig. 3, upper panel) .
Compliance Results
Compliance data were available for all subjects; in subjects randomized to active drug, overall compliance was more than 99%. Five of 22 subjects receiving active drug missed 1 dose, and 1 subject missed 2 doses.
Side-effects
Treatment with MK-677 was generally well tolerated. There were no serious clinical or laboratory adverse experiences. There were three reports in panel A of mild abdominal pain and five reports of mild appetite increase in panels A and B (all in drug-treated subjects). Body weight did not change significantly with MK-677 treatment.
Examination of individual 24-h GH concentration profiles (Fig. 4) suggested that MK-677 treatment enhanced pulsatile GH release rather than a sustained increase in serum GH concentrations. This interpretation was supported by the results of Cluster analysis (Table l) , which revealed that treatment with 10 and 25 mg MK-677 resulted in statistically significant increases in the height of GH pulses and interpeak nadir GH concentrations, without any change in the number of GH pulses. Similar results were obtained with the Ultra peak detection algorithm (data not shown). Multiple parameter deconvolution analysis (6, 24) indicated that the increases in serum GH concentrations resulted from increased GH secretion without changes in GH clearance rates. Treatment with 25 mg MK-677 for 14 days resulted in a 1.7-fold increase in the amount of GH secreted per 24 h compared to baseline (277 + 32 VS. 164 + 27 pg; P = 0.017) without a significant change in GH disappearance half-life (21.0 + 1.7 VS. 20.2 ? 0.8 min). The increase in GH secretion was accounted for by a 1.6-fold increase in the mass of GH secreted per pulse (3.3 -t 0.4 vs. 2.1 2 0.3 pg/L distribution volume; P = 0.045) without a significant change in the number of GH secretory pulses per 24 h (13.1 ? 0.5 vs. 11.9 2 0.8) or the contribution of basal secretion to total 24-h production (20 2 3.7% vs. 17.6 + 4%). The second, independent deconvolution technique (5) estimated the increase in 24-h GH production rates with 25 mg MK-677 to be slightly larger (364 + 20 vs. 178 2 8 pg/24 h; P = 0.011) due to shorter estimates of the GH half-life (16.7 + 0.8 min).
Effect of evening MK-677 treatment GH. Oral administration of MK-677 produced dose-depen-IGF-I. Administration of MK-677 also resulted in dose-dedent increases in mean 24-h GH concentrations (Fig. 2) , pendent increases in serum IGF-I concentrations ( per L) after 2 and 4 weeks of treatment (lower panel) with placebo (n = 10) and once daily oral evening (PM) MK-677 doses of 2 mg(n = lo), 10 mg(n = 121, and 25 mg (n = 10). *, Significant change from baseline (P 5 0.05).
Fig. 3, lower panel). The highest dose (25 mg/ day) increased IGF-I concentrations
55 + 10% (-1.5-155%) at 2 weeks and 88 t 16% (33-202%) at 4 weeks. Serum IGF-I concentrations increased in all subjects treated with 25 mg / day. In 8 of the 10 subjects, IGF-I concentrations were within the normal range for adults 21-25 yr old after 4 weeks of treatment compared to 2 of 10 subjects at baseline (Fig. 5) . The mean IGF-I concentration of these 10 subjects increased into the young adult normal range after both 2 and 4 weeks.
Comparison of evening us. morning treatment with 10 mglday MK-677 GH. The 24-h mean GH profiles after evening and morning administration of placebo or 10 mg/ day MK-677 are shown in Fig. 6 . The 24-h mean GH percent increase from baseline was significant after both morning and evening oral admin- istration of 10 mg MK-677 for 2 weeks (Fig. 7, fop panel) . Although 24-h mean GH and GH peak height were numerically higher (P = 0.09 and P = 0.11, respectively), only the interpeak nadir GH concentrations were significantly different (P = 0.01; Table 1 ).
IGF-I. The IGF-I response after 2 weeks of 10 mg MK-677 morning treatment was significantly greater than that after evening treatment (164 ? 15 us. 182 % 15; P < 0.05; Table 1 and Fig. 7, loruer pnrzel) .
Although there was a trend toward a greater response to the drug in older subjects, the response to MK-677 in indi- vidual subjects could not be predicted from any baseline measurement.
For example, in the 10 subjects treated with 25 mg/day MK-677, no significant correlations (P > 0.1) were detected between the percent changes in either the mean 24-h mean GH concentration or the serum IGF-I concentration after 2 weeks of treatment and any of the following baseline measurements:
mean 24-h GH concentration, IGF-I concentration, age, BMI, or age-BMI product.
Other hormone and glucose results
Results of treatment with 2 mg MK-677 are not shown, as there were no associated significant changes in any parameter. Serum cortisol concentrations were determined every 20 min for 24 h in all panel A subjects. Mean serum cortisol was not significantly different from baseline after 25 mg MK-677 for 14 days (mean -C SE, 226.2 2 5.5 VS. 231.8 2 5.5 nmol/L; P = 0.31), and the ultradian pattern of serum cortisol concentrations was preserved (Fig. 8) . Similarly, 24-h urinary free cortisol measurements were not significantly different (data not shown).
The mean serum PRL concentration increased 24% after the administration of 25 mg MK-677 (mean ? SE, 7 k 0.5 to 8.6 2 0.7 pg/L; P 5 0.01 VS. baseline). No gender-associated differences in this response were detected. Serum T, and TSH were not significantly affected by MK-677 treatment. T, concentrations were significantly lower than baseline after 2 weeks of treatment with both placebo and 25 mg MK-677; the changes in the MK-677-treated group were not significantly different from those in the control group. The effects of evening treatment with 10 and 25 mg MK-677 on IGF-II; IGF-binding protein-l (IGFBP-l), -2, and -3; fasting glucose; and fasting insulin concentrations are shown in Table  2 . MK-677 treatment was associated with statistically significant increases in fasting concentrations of IGF-II, IGF-BP-3, glucose, and insulin and decreases in IGFBP-1 and -2.
Pretreatment fasting blood glucose concentrations were below 8 mmol/L (144 mg/dL) in all subjects. MK-677 treat- of 10 mg/day MK-677 for 2 weeks in the evening (PM) VS. morning (AM) administration of the same dose (n = 12). *, P < 0.05 us. placebo (n = 10); +, P < 0.05, AM us. PM dosing. ment was associated with statistically significant dose-dependent increases in fasting blood glucose concentrations. After the administration of 25 mg MK-677, glucose concentrations had increased 25.3 2 6.6% and 26.9 2 6.8% above baseline by 2 and 4 weeks, respectively. Three of the 10 subjects who received 25 mg/day and 1 of the 12 who received 10 mg/day had increases in fasting glucose concentrations to above 8 mmol/ L at either 2 or 4 weeks compared to none of the placebo-treated subjects. The highest fasting blood glucose level measured was 9.7 mmol/L in a subject who had received 10 mg MK-677 for 2 weeks in the evening. The change in glucose after administration of 25 mg MK-677 correlated with BMI (r = 0.77; P < 0.01).
Discussion
Once daily oral administration of MK-677 to older adults increased serum GH concentrations in a dose-dependent manner by enhancing pulsatile GH secretion. Serum IGF-I concentrations increased into the normal range for young adults in 8 of 10 subjects after 4 weeks of treatment with 25 mg/day MK-677, with a mean increase of 88%. Administration of MK-677 in the morning resulted in greater increases in serum IGF-I compared to the effects of evening treatment. This is the first study to demonstrate that serum GH and IGF-I concentrations can be increased in older adults by chronic administration of an oral GH secretagogue. MK-677 is a spiropiperidine that mimics the actions of 20) . Both MK-677 and GHRP-6 bind to the same unique non-GHRH, nonsomatostatin receptors in the pituitary to stimulate GH secretion via protein kinase C-and calcium-dependent mechanisms (17) (18) (19) (20) (26) (27) (28) (29) . In addition to direct effects on the pituitary, MK-677 and GHRP-6 probably act on the hypothalamus (17). GHRP-6 has greatly reduced GH-releasing efficacy when administered to subjects with hypothalamic-pituitary disconnection (30, 31) and has a synergistic stimulatory effect on GH secretion when coadministered with GHRH (32). This suggests that it acts as a functional somatostatin antagonist and/or releases another, as yet unidentified, hypothalamic releasing factor (17). Both GHRP-6 and the GHRP-mimetic secretagogues stimulate the hypothalamic arcuate nucleus neurons in which GHRH is synthesized (33, 34) . In sheep, hexarelin, a GHRP-6 analog, stimulates hypothalamic secretion of GHRH (35). In older adults, the GH response to GHRP-6 and GHRP-mimetic secretagogues is greater than that to GHRH (21, 36) .
The net effect of these actions is that both GHRP-6 (16) and MK-677 enhance the preexisting pulsatile pattern of GH secretion. The primary effect of aging on GH secretion is to decrease the amplitude of GH pulses (5, 6). Oral administration of MK-677 partially reversed these effects of aging by increasing both the height of the GH pulses and the nadir GH concentrations between pulses. These higher serum GH concentrations resulted from an increased mass of GH secreted per pulse, with no significant change in the number of GH secretory pulses or the half-life of GH clearance. Similar effects in older adults were observed with a continuous iv infusion of a related compound, L-692,429 (37). The increased interpeak GH concentrations may be the result of increased basal (nonpulsatile) secretion or the larger GH secretory pulses (i.e. with larger pulses, the GH concentrations do not decline to baseline before the onset of the next pulse). Nevertheless, it is clear that the majority of GH secretion remained pulsatile during MK-677 treatment. Whereas basal secretion accounts for 38-69% of 24-h GH production in acromegaly (38), less than 20% of GH secretion was attributable to basal secretion during MK-677 treatment.
As the metabolic actions of GH are modulated by the pattern of GH exposure to tissues (39), we speculate that enhancement of pulsatile GH release may produce fewer side-effects and greater benefits than the sustained increase in GH concentrations produced by daily SC GH administration (15), but this remains to be determined.
The greater stimulation of GH release by morning than evening MK-677 administration was an unexpected finding, although a similar conclusion had been suggested by two earlier studies. However, both of those studies unfortunately were limited by the use of less sensitive GH assays (16, 40 MK-677 restored serum IGF-I concentrations in most older subjects to levels seen in young adults. Administration of 10 mg/day MK-677 in the morning increased IGF-I to a greater extent than treatment in the evening. Further studies are needed to establish the long term safety of this drug, particularly its effect on glucose and insulin levels, and to determine the effect of long term administration of such compounds in a variety of conditions associated with GH deficiency.
Our findings suggest that oral GH secretagogues may provide significant therapeutic advantages over administration of GH in these conditions.
